PureTech Health plc (PTCHF)
USD 1.75
(-5.91%)
USD 1.75
(-5.91%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 693.97 Million USD | -1.23% |
| 2022 | 702.64 Million USD | -25.72% |
| 2021 | 946 Million USD | -4.44% |
| 2020 | 989.99 Million USD | 5.19% |
| 2019 | 941.17 Million USD | 113.05% |
| 2018 | 441.76 Million USD | 29.99% |
| 2017 | 339.84 Million USD | 13.76% |
| 2016 | 298.74 Million USD | -8.57% |
| 2015 | 326.75 Million USD | 43.3% |
| 2014 | 228.02 Million USD | 1260.06% |
| 2013 | 16.76 Million USD | -12.61% |
| 2012 | 19.18 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 579.95 Million USD | 0.0% |
| 2024 Q1 | 579.95 Million USD | -16.43% |
| 2023 Q1 | 693.55 Million USD | -1.29% |
| 2023 Q3 | 693.97 Million USD | 0.06% |
| 2023 Q2 | 693.55 Million USD | 0.0% |
| 2023 FY | 693.97 Million USD | -1.23% |
| 2023 Q4 | 693.97 Million USD | 0.0% |
| 2022 Q1 | 823.15 Million USD | -12.99% |
| 2022 Q2 | 823.15 Million USD | 0.0% |
| 2022 FY | 702.64 Million USD | -25.72% |
| 2022 Q3 | 702.64 Million USD | -14.64% |
| 2022 Q4 | 702.64 Million USD | 0.0% |
| 2021 FY | 946 Million USD | -4.44% |
| 2021 Q2 | 896.88 Million USD | 0.0% |
| 2021 Q3 | 946 Million USD | 5.48% |
| 2021 Q1 | 896.88 Million USD | -9.41% |
| 2021 Q4 | 946 Million USD | 0.0% |
| 2020 Q1 | 1.1 Billion USD | 17.46% |
| 2020 Q3 | 989.99 Million USD | -10.45% |
| 2020 Q4 | 989.99 Million USD | 0.0% |
| 2020 FY | 989.99 Million USD | 5.19% |
| 2020 Q2 | 1.1 Billion USD | 0.0% |
| 2019 Q3 | 941.17 Million USD | 52.21% |
| 2019 FY | 941.17 Million USD | 113.05% |
| 2019 Q2 | 618.33 Million USD | 0.0% |
| 2019 Q1 | 618.33 Million USD | 39.97% |
| 2019 Q4 | 941.17 Million USD | 0.0% |
| 2018 Q1 | 434.87 Million USD | 27.96% |
| 2018 FY | 441.76 Million USD | 29.99% |
| 2018 Q4 | 441.76 Million USD | 0.0% |
| 2018 Q3 | 441.76 Million USD | 1.58% |
| 2018 Q2 | 434.87 Million USD | 0.0% |
| 2017 Q1 | 269.46 Million USD | -9.8% |
| 2017 FY | 339.84 Million USD | 13.76% |
| 2017 Q4 | 339.84 Million USD | 0.0% |
| 2017 Q3 | 339.84 Million USD | 26.12% |
| 2017 Q2 | 269.46 Million USD | 0.0% |
| 2016 Q1 | 313.75 Million USD | -3.98% |
| 2016 FY | 298.74 Million USD | -8.57% |
| 2016 Q4 | 298.74 Million USD | 0.0% |
| 2016 Q3 | 298.74 Million USD | -4.78% |
| 2016 Q2 | 313.75 Million USD | 0.0% |
| 2015 Q3 | 326.75 Million USD | 7.67% |
| 2015 FY | 326.75 Million USD | 43.3% |
| 2015 Q4 | 326.75 Million USD | 0.0% |
| 2015 Q2 | 303.49 Million USD | 0.0% |
| 2015 Q1 | 303.49 Million USD | 33.09% |
| 2014 Q4 | 228.02 Million USD | 221.04% |
| 2014 Q3 | 71.02 Million USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 FY | 228.02 Million USD | 1260.06% |
| 2013 FY | 16.76 Million USD | -12.61% |
| 2012 FY | 19.18 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | -30042021.212% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -35339.531% |
| Evofem Biosciences, Inc. | 10.55 Million USD | -6475.45% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -125592.422% |
| Rebus Holdings, Inc. | 5000.00 USD | -13879360.0% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | -432.961% |
| Qrons Inc. | 420.00 USD | -165231566.667% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -89951.048% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | -2383.442% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -144310.132% |
| Skye Bioscience, Inc. | 11.94 Million USD | -5711.969% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | -1686.426% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -9512.131% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -908788.86% |
| SQZ Biotechnologies Company | 107.18 Million USD | -547.441% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -48360.719% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -958889.843% |
| Mesoblast Limited | 667.9 Million USD | -3.904% |
| Marizyme, Inc. | 22.01 Million USD | -3052.263% |
| Genus plc | 1.02 Billion USD | 32.552% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -50989.297% |
| Pharming Group N.V. | 462.85 Million USD | -49.933% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -20846.891% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -138961.877% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -110581.499% |
| ContraFect Corporation | 20.67 Million USD | -3255.931% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -177674.96% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -181484.187% |
| IMV Inc. | 31.33 Million USD | -2114.775% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -16638.286% |
| MultiCell Technologies, Inc. | 126.22 USD | -549812132.61% |
| ONE Bio Corp. | 70.08 Million USD | -890.18% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -73751.349% |
| RVL Pharmaceuticals plc | 128.51 Million USD | -440.015% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | -160648.319% |
| Q BioMed Inc. | 3.51 Million USD | -19640.283% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | -1872.691% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -265508.148% |
| Biomind Labs Inc. | 73.81 Thousand USD | -940000.787% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | -55.492% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -47798.427% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | -2212.091% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -25169.059% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -100843.583% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -26558.5% |
| GB Sciences, Inc. | 103.44 Thousand USD | -670781.267% |
| Alpha Cognition Inc. | 2.45 Million USD | -28200.363% |
| HST Global, Inc. | 1526.00 USD | -45476505.505% |
| CSL Limited | 38.02 Billion USD | 98.175% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -70142.528% |
| Halberd Corporation | 10.13 Thousand USD | -6849895.065% |
| Enzolytics Inc. | 361.7 Million USD | -91.861% |
| Agentix Corp. | 261.39 Thousand USD | -265391.293% |
| Resverlogix Corp. | 8.11 Million USD | -8451.731% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -36855.13% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 84.723% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | -1354.809% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -108391.595% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -3046179.795% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | -7654.62% |
| AVAX Technologies, Inc. | 7.37 Million USD | -9307.052% |
| Zenith Capital Corp. | 7410.00 USD | -9365257.625% |
| Genscript Biotech Corporation | 3.38 Billion USD | 79.507% |
| Ember Therapeutics, Inc. | 184.00 USD | -377159139.13% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -215549.491% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -265419.735% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -74684.716% |
| Kadimastem Ltd | 2.3 Million USD | -30019.31% |
| Helix BioMedix, Inc. | 3.02 Million USD | -22840.604% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | -1216.812% |
| BioStem Technologies, Inc. | 14.56 Million USD | -4666.203% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -1215391.996% |
| LadRx Corporation | 2.3 Million USD | -29969.692% |
| Cell Source, Inc. | 195.17 Thousand USD | -355471.781% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -196149.897% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -196149.897% |
| NovAccess Global Inc. | 62.24 Thousand USD | -1114751.883% |
| Affymax, Inc. | 7.44 Million USD | -9223.834% |
| Itoco Inc. | 1.4 Million USD | -49466.951% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -725380.623% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -654591.509% |
| Mobile Lads Corp. | 52.00 USD | -1334563361.538% |
| CytoDyn Inc. | 11.13 Million USD | -6131.798% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -485290.846% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -3881180.761% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -179932.48% |
| SYBLEU INC | 330.46 Thousand USD | -209897.035% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -169400.662% |
| International Stem Cell Corporation | 5.39 Million USD | -12775.195% |
| Bioxytran, Inc. | 137.63 Thousand USD | -504101.601% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | -4525.922% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | -4085.856% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -878346.835% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -80158.062% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -9132.047% |
| Neutra Corp. | 2851.00 USD | -24341288.986% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -2041.495% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -8498.257% |
| IXICO plc | 15.84 Million USD | -4280.063% |
| IntelGenx Technologies Corp. | 8.28 Million USD | -8279.292% |
| Gelesis Holdings, Inc. | 103.32 Million USD | -571.647% |
| CSL Limited | 38.02 Billion USD | 98.175% |
| Cellectis S.A. | 333.99 Million USD | -107.78% |